Pfizer, Pharmaceutical company

London, Oct 14 With Covid-19 proving the credibility of mRNA technology, many drug companies are racing to apply the same formula for developing vaccines for influenza, Nature reported.While Moderna, Pfizer and Sanofi have, in recent months, initiated Phase 1 trials of mRNA-based seasonal flu vaccine candidates, more companies intend to follow their leads next year.However, unlike Covid-19, mRNA-based flu shots could also prove a more challenging test as nine flu jabs from four different vaccine manufacturers are already available in the US alone.Although the shots built around inactivated viruses or recombinant proteins are safe, they typically offer only 40-60 per cent protection from infection.At the same time, mRNA-based jabs might produce broader immune responses, better sequence fidelity of proteins, and accurate strain selection. Moreover, the technology makes it easy to incorporate large numbers of antigens all of which could translate into greater immune protection, the report said.But mRNA is also prone to tolerability issues, as seen in Covid shots developed by Moderna and Pfizer they often cause sore arms, headaches, low-grade fevers and fatigue. These same symptoms can occur with approved flu shots, but typically are much milder in degree.On the other hand, the potential benefits of mRNA for preventing flu are many, majorly because of how it is manufactured."Because mRNA vaccines are manufactured synthetically, by encoding a target antigen sequence into a plasmid template, they offer high fidelity: encoded antigens exactly match the flu strains selected for each year's vaccine.The recombinant protein vaccines also offer that same fidelity advantage, but the manufacturing process for these is comparatively cumbersome.The flexibility and speed of mRNA vaccine production also means that drug makers could wait longer to begin manufacturing starting production in May, say, instead of February, for the northern hemisphere. This would enable them to make more informed decisions about what strains to include, the report said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

PfizerFOLLOW

Pfizer, Latest News

Washington, Oct 23 Pfizer and its partner BioNTech said their Covid-19 vaccine is safe and 90.7 per cent ... ...

Washington, Oct 22 Pfizer and BioNTech has announced that a large-scale trial of their Covid-19 vaccine booster showed ... ...

Pfizer and BioNTech said on Thursday that a booster shot of their COVID-19 vaccine has shown 95.6 per cent efficacy when compared to those who did not receive the booster dose. ...

The Australian government has secured access to two new COVID-19 treatments as the country continues to battle the third wave of infections. ...

Austrian President Alexander Van der Bellen invited citizens on Saturday to come by on October 26 and get their COVID-19 vaccine shots in the splendid marble hall of the imperial Hofburg Palace. ...

Sri Lankan health authorities on Friday began administering the COVID-19 vaccines on school students between the ages of 18 and 19 with the Pfizer doses amidst a large-scale vaccination program ongoing in the country since January. ...

Recently, controversy has arisen as several people are complaining of hair loss after receiving the COVID-19 vaccination. It has not yet been proven that the COVID-19 vaccine causes hair loss, but experts say that the possibility of side effects cann ...

London, Oct 14 With Covid-19 proving the credibility of mRNA technology, many drug companies are racing to apply ... ...